| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/21/2006 | EP1670446A2 Method of inhibiting remnant lipoprotein production |
| 06/21/2006 | EP1670445A2 Methods of preventing or treating recurrence of myocardial infarction |
| 06/21/2006 | EP1670444A2 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
| 06/21/2006 | EP1670443A2 Aerosol formulation comprising formoterol in suspension |
| 06/21/2006 | EP1670442A1 Delayed released dosage forms |
| 06/21/2006 | EP1670441A1 Rapidly disintegrating formulation |
| 06/21/2006 | EP1670440A1 Hrt formulations |
| 06/21/2006 | EP1670438A2 Dry powder composition comprising a benzodiazepine for pulmonary inhalation |
| 06/21/2006 | EP1670437A1 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin |
| 06/21/2006 | EP1670432A1 Aerosol formulations comprising formoterol fumarate dihydrate, a propellant, ethanol and optionally a steroid, where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight. |
| 06/21/2006 | EP1670427A2 Methods and reagents for the treatment of immunoinflammatory disorders |
| 06/21/2006 | EP1670418A2 Chitosan spinning method, device therefor, and resulting chitosan yarn, and uses thereof |
| 06/21/2006 | EP1670417A2 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischenic mediated central nervous system disorders or injury |
| 06/21/2006 | EP1670416A2 Methods for treating igf1r-inhibitor induced hyperglycemia |
| 06/21/2006 | EP1670415A2 Animal model for protease activity and liver damage |
| 06/21/2006 | EP1670325A1 SOLUBILIZED CoQ-10 |
| 06/21/2006 | EP1562576B1 Enhancement of alcohol metabolism |
| 06/21/2006 | EP1539160B1 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders |
| 06/21/2006 | EP1515705B1 Fluorosiloxane matrix controlled diffusion drug delivery system |
| 06/21/2006 | EP1506193B1 Carbamate-substituted pyrazolopyridines |
| 06/21/2006 | EP1501516B1 A process for the preparation of benazepril hydrochloride |
| 06/21/2006 | EP1463504B1 Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome |
| 06/21/2006 | EP1450797B1 Benzothiazole derivatives |
| 06/21/2006 | EP1450781B1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 06/21/2006 | EP1448753B1 Conditioning solution for contact lenses |
| 06/21/2006 | EP1443915B1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
| 06/21/2006 | EP1438316B1 Phosphonic acid compounds as inhibitors of serine proteases |
| 06/21/2006 | EP1437126B1 Compositions used to alleviate xerostomia and to treat disorders associated with same |
| 06/21/2006 | EP1434589A4 Thioester-terminated water soluble polymers and method of modifying the n-terminus of a polypeptide therewith |
| 06/21/2006 | EP1423147B1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 06/21/2006 | EP1420646B1 Antimicrobial agent |
| 06/21/2006 | EP1406654A4 Methods for regulating bacteria |
| 06/21/2006 | EP1401415B1 Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases |
| 06/21/2006 | EP1392325B1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
| 06/21/2006 | EP1383508B1 Doxycycline for the treatment of acne |
| 06/21/2006 | EP1366049B1 Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives |
| 06/21/2006 | EP1365766B1 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 06/21/2006 | EP1345624B1 Induction of tolerance |
| 06/21/2006 | EP1341779B1 Heterocyclic sulfonamide inhibitors of beta amyloid production |
| 06/21/2006 | EP1337279B1 Sterilisation of glucocorticosteriode suspensions |
| 06/21/2006 | EP1326595B1 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
| 06/21/2006 | EP1309322B1 Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders |
| 06/21/2006 | EP1305047B1 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection |
| 06/21/2006 | EP1305020B1 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure |
| 06/21/2006 | EP1303306B1 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 06/21/2006 | EP1284952B1 Substituted chalcones as therapeutic compounds |
| 06/21/2006 | EP1282599B1 Disulfide derivatives useful for treating allergic diseases |
| 06/21/2006 | EP1276476B1 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 06/21/2006 | EP1268419B1 Pyrrolidine derivatives useful as bax inhibitors |
| 06/21/2006 | EP1267976B1 Microencapsulated fragrances and methods of coating microcapsules |
| 06/21/2006 | EP1267866B1 The treatment of respiratory diseases |
| 06/21/2006 | EP1265617B1 Novel topical oestroprogestational compositions with systemic effect |
| 06/21/2006 | EP1263440B1 Cephalotaxine alkaloid combination compositions and uses thereof |
| 06/21/2006 | EP1255734B1 Isatine derivatives with neurotrophic activity |
| 06/21/2006 | EP1251850B1 Use of a combination preparation in cancer therapy |
| 06/21/2006 | EP1250321B1 Glyburide composition |
| 06/21/2006 | EP1244647B1 Quinazoline derivatives as vegf inhibitors |
| 06/21/2006 | EP1227810B1 Treating cancer by increasing intracellular malonyl coa levels |
| 06/21/2006 | EP1208092B1 Sulfonamide derivative as a matrix metalloproteinase inhibitor |
| 06/21/2006 | EP1200094B1 Ophthalmic compositions containing antibiotics and nsaids |
| 06/21/2006 | EP1173163B1 Pharmaceutical compositions of tetrac and methods of use thereof |
| 06/21/2006 | EP1171583B1 A multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
| 06/21/2006 | EP1171133B1 R-hydroxynefazodone |
| 06/21/2006 | EP1146872B1 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction |
| 06/21/2006 | EP1128835B1 Cyanocobalamin (vitamin b 12) treatment in allergic disease |
| 06/21/2006 | EP1123278B1 Method for producing (+)-exo-6-phenyl-3-azabicyclo- 3.2.0|heptanes |
| 06/21/2006 | EP1051208B1 Hydrophilic coating for an intracorporeal medical device |
| 06/21/2006 | EP1049662B1 Inhibitors of alpha4 mediated cell adhesion |
| 06/21/2006 | EP1044186B9 Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| 06/21/2006 | EP1025106B1 Allosteric adenosine receptor modulators |
| 06/21/2006 | EP1007089B1 Anticoagulant humanised antibodies against factor IX, for use in the treatment of thrombosis |
| 06/21/2006 | EP0957080B1 Novel ethylamine derivatives |
| 06/21/2006 | EP0947502B1 Novel sulfur-containing amino acid derivatives |
| 06/21/2006 | EP0941039A4 Transdermal administration of ment |
| 06/21/2006 | EP0939639B1 Methods and compositions for reducing or eliminating post-surgical adhesion formation |
| 06/21/2006 | EP0932398B1 Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders |
| 06/21/2006 | EP0923600B1 Novel cationic amphiphilic lipids for liposomal gene transfer |
| 06/21/2006 | EP0920316B1 Treatment of manic disorders |
| 06/21/2006 | EP0912198B1 Immunoliposomes that optimize internalization into target cells |
| 06/21/2006 | EP0815100B1 Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 06/21/2006 | EP0754044B1 Novel iron chelator and inhibitor of iron-mediated oxidation |
| 06/21/2006 | EP0661973B1 Method of preventing nmda receptor complex-mediated neuronal damage |
| 06/21/2006 | EP0613560B2 A method for assaying and treating alzheimer's disease |
| 06/21/2006 | CN1792021A DC motor |
| 06/21/2006 | CN1791611A 17beta-hydroxysteroid dehydrogenase inhibitors. |
| 06/21/2006 | CN1791610A Oestrogen derivatives as inhibitors of steroid sulphatase. |
| 06/21/2006 | CN1791608A 6r-(3,6-dideoxy-l-arabino-hexopyranosyloxy)heptanoic acid, preparation process for the same and dauer effect thereof |
| 06/21/2006 | CN1791604A Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| 06/21/2006 | CN1791603A Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| 06/21/2006 | CN1791601A Azaindole-derivatives as factor Xa inhibitors |
| 06/21/2006 | CN1791600A Benzothiazole derivatives as adenosine receptor ligands |
| 06/21/2006 | CN1791599A 丙型肝炎抑制剂化合物 Hepatitis C inhibitor compounds |
| 06/21/2006 | CN1791598A Benzimidazole-derivatives as factor Xa inhibitors |
| 06/21/2006 | CN1791596A Anti-cancer medicaments |
| 06/21/2006 | CN1791594A 2-aminoquinoline derivative |
| 06/21/2006 | CN1791593A Pyridinyl carbamates |
| 06/21/2006 | CN1791592A 免疫抑制剂化合物和组合物 Immunosuppressant compounds and compositions |
| 06/21/2006 | CN1791591A Bioreductively-activated prodrugs |
| 06/21/2006 | CN1791585A Cyclic sulfonamides for inhibition of gamma-secretase. |
| 06/21/2006 | CN1791580A Biaryl substituted 6-membered heterocyles as sodium channel blockers |